The MMPR guideline has been updated to address incorrect values related to alfaboldenone, methylboldenone, and methyltestosterone in urine.

Reasons for change: Data transfer errors when taking over values from version 2.1

The revised EURL-MMPR Guidance (Version 3.0, April 2026) is now available, replacing Version 2.1.

Over the past few years, the EURLs active in the field of veterinary medicinal product residues (VMPR) analysis in cooperation with the NRLs have published several EURL Guidance Documents supporting the implementation of Commission Implementing Regulation 2021/808. The Guidance Documents represent the EURL interpretation of CIR 2021/808 and are meant as a support for all laboratories, furthering the harmonised implementation of CIR 2021/808. However, the Guidance Documents are not seen as mandatory to follow, and other approaches are possible if comparable results are achieved.

During the discussions for the preparation of a database of stability information for VMPR analysis, it has become clear that the laboratory network would benefit from information on the performance of stability assessments supplementing the prescriptions given in CIR 2021/808. The stability database working group with representatives from the NRLs Belgium, Ireland, Slovenia, and the three EURLs has therefore compiled a final EURL Guidance Document on Stability Studies.

Now, the EURL Guidance Document on Stability Studies has been finalised and is available as of today. This document spans all aspects of stability studies including their design, the selection of samples to be studied, study evaluation, examples, as well as the applicability of data from external sources to the conditions in another laboratory.